CA2948219C - Method for adjusting the release of active agent in a transdermal delivery system - Google Patents

Method for adjusting the release of active agent in a transdermal delivery system Download PDF

Info

Publication number
CA2948219C
CA2948219C CA2948219A CA2948219A CA2948219C CA 2948219 C CA2948219 C CA 2948219C CA 2948219 A CA2948219 A CA 2948219A CA 2948219 A CA2948219 A CA 2948219A CA 2948219 C CA2948219 C CA 2948219C
Authority
CA
Canada
Prior art keywords
active agent
accordance
additive
layer
copolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2948219A
Other languages
English (en)
French (fr)
Other versions
CA2948219A1 (en
Inventor
Marco Emgenbroich
Johannes Josef Leonhard
Hans-Michael Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50735939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2948219(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of CA2948219A1 publication Critical patent/CA2948219A1/en
Application granted granted Critical
Publication of CA2948219C publication Critical patent/CA2948219C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2948219A 2014-05-20 2015-05-20 Method for adjusting the release of active agent in a transdermal delivery system Active CA2948219C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169026 2014-05-20
EP14169026.3 2014-05-20
PCT/EP2015/061109 WO2015177209A1 (en) 2014-05-20 2015-05-20 Method for adjusting the release of active agent in a transdermal delivery system

Publications (2)

Publication Number Publication Date
CA2948219A1 CA2948219A1 (en) 2015-11-26
CA2948219C true CA2948219C (en) 2023-04-04

Family

ID=50735939

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2948219A Active CA2948219C (en) 2014-05-20 2015-05-20 Method for adjusting the release of active agent in a transdermal delivery system

Country Status (6)

Country Link
US (2) US11426359B2 (enExample)
EP (1) EP3145503A1 (enExample)
JP (2) JP6895755B2 (enExample)
CN (1) CN106456567A (enExample)
CA (1) CA2948219C (enExample)
WO (1) WO2015177209A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
TWI687239B (zh) * 2015-10-26 2020-03-11 日商久光製藥股份有限公司 貼附劑
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
KR102506333B1 (ko) 2016-12-20 2023-03-06 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피흡수 치료 시스템
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
FI3854388T3 (fi) * 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315272C2 (de) 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5032207A (en) 1988-03-04 1991-07-16 Noven Pharmaceuticals, Inc. One-step method for forming a pressure-sensitive adhesive transdermal drug device
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5405486A (en) 1988-03-04 1995-04-11 Noven Pharmaceuticals, Inc. Apparatus for forming a transdermal drug device
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4994278A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US4814168A (en) 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US5300291A (en) 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
EP0474647B1 (en) 1990-03-28 1997-02-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
AU2004092A (en) 1991-04-25 1992-12-21 Noven Pharmaceuticals, Inc. Method and apparatus for forming a transdermal drug device
US5387189A (en) 1993-12-02 1995-02-07 Alza Corporation Electrotransport delivery device and method of making same
EP0988707A2 (en) 1998-03-20 2000-03-29 Koninklijke Philips Electronics N.V. Receiver with a clock signal generator
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6757560B1 (en) 1999-04-09 2004-06-29 Novosis Pharma Ag Transdermal delivery system (TDS) with electrode network
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6317630B1 (en) 1999-01-29 2001-11-13 Yossi Gross Drug delivery device
EP1189660B1 (en) 1999-06-08 2006-05-03 Altea Therapeutics Corporation Apparatus for microporation of biological membranes using thin film tissue interface devices, and method therefor
PL197492B1 (pl) 1999-07-02 2008-04-30 Lohmann Therapie Syst Lts Transdermalny system terapeutyczny zawierający warstwę polimerową z zawartymi w niej mikrozbiornikami i sposób wytwarzania błon
DE10012908B4 (de) 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
KR20030087048A (ko) 2001-04-02 2003-11-12 아스트라제네카 아베 4-시아노-트리플루오로-3-(4-플루오로페닐설포닐)-2-히드록시-2-메틸프로피오노-ｍ 톨루이다이드 및 ｐｖｐ를포함하는 고체 약학 조성물
DE10118282A1 (de) 2001-04-12 2002-12-05 Lohmann Therapie Syst Lts Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke
DK1256339T3 (da) 2001-05-08 2004-02-09 Sanol Arznei Schwarz Gmbh Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
ES2203563T3 (es) 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
EP1453447A4 (en) 2001-08-17 2006-06-07 Lavipharm Lab Inc COMPOSITION AND DEVICE FOR TRANSDERMAL DRUG DELIVERY
DE10159745A1 (de) 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
US6775570B2 (en) 2002-02-04 2004-08-10 Ceramatec, Inc. Iontophoretic treatment device
US20030180281A1 (en) 2002-03-11 2003-09-25 Bott Richard R. Preparations for topical skin use and treatment
US20060263419A1 (en) 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
DE10220230A1 (de) 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
EP1386604A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
EP1386605A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE60204229T2 (de) 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
CN100403477C (zh) 2003-01-02 2008-07-16 Cymbet公司 固态电池供电装置及其制造方法
US7603144B2 (en) 2003-01-02 2009-10-13 Cymbet Corporation Active wireless tagging system on peel and stick substrate
RU2349315C9 (ru) 2003-04-14 2010-02-27 Лтс Ломанн Терапи-Системе Аг Терапевтический пластырь с полисилоксановой матрицей, содержащей капсаицин
WO2005000924A1 (en) 2003-06-26 2005-01-06 Symyx Technologies, Inc. Photoresist polymers
WO2005009417A1 (en) 2003-07-21 2005-02-03 Noven Pharmaceuticals, Inc. Composition and method for controlling grug delivery from silicone adhesive blends
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361259A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US20050202073A1 (en) 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
ATE384318T1 (de) 2004-05-28 2008-02-15 Geest Jan De Kommunikationseinheit für die haut einer person
JP2006178807A (ja) 2004-12-24 2006-07-06 Echigo Fudagami Kk Ｉｃシート製造装置及びｉｃシート製造方法
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102006054733A1 (de) 2006-11-21 2008-05-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches Systems mit hoher Wirkstoffausnutzungsrate und Dosiergenauigkeit
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
EP2178598A4 (en) 2007-08-17 2012-08-15 Isis Biopolymer Llc IONTOPHORETIC DRUG DISTRIBUTION SYSTEM
WO2009026940A1 (de) 2007-08-24 2009-03-05 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von von cycloheximid abgeleiteten verbindungen zur behandlung oder vorbeugung von insbesondere ischämien und herzerkrankungen
US20090143423A1 (en) 2007-10-19 2009-06-04 Abbott Gmbh & Co. Kg Solid dispersion product containing n-aryl urea-based compound
MY165575A (en) 2007-11-28 2018-04-05 Ucb Pharma Gmbh Polymorphic form of rotigotine
CA2726136C (en) 2008-05-30 2016-11-01 Mylan Laboratories, Inc. Stabilized transdermal drug delivery system
JP2009297808A (ja) 2008-06-11 2009-12-24 Chiyoda Integre Co Ltd 粘着テープ製造方法及び粘着テープ製造装置
EP2140861A1 (en) 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
AR074047A1 (es) 2008-09-09 2010-12-22 Transcu Ltd Sistemas, dispositivos, y metodos para suministrar energia a dispositivos, por ejemplo dispositivos de administracion transdermica y/o para controlarlos
AU2009302853B2 (en) 2008-10-06 2014-09-11 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
SG175341A1 (en) 2009-05-08 2011-11-28 Isis Biopolymer Inc Iontophoretic device with improved counterelectrode
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
DE102009052972A1 (de) * 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
CN102665699A (zh) * 2009-12-22 2012-09-12 优时比制药有限公司 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮
CA2817824A1 (en) 2010-11-23 2012-05-31 Nupathe, Inc. User-activated self-contained co-packaged iontophoretic drug delivery system
WO2012084969A1 (en) * 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102012013421A1 (de) * 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
TW201338813A (zh) 2011-12-12 2013-10-01 Lohmann Therapie Syst Lts 經皮遞送系統
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
AU2014276910B2 (en) 2013-06-04 2017-03-09 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system

Also Published As

Publication number Publication date
BR112016027143A2 (pt) 2017-08-15
US20170079932A1 (en) 2017-03-23
EP3145503A1 (en) 2017-03-29
CA2948219A1 (en) 2015-11-26
US11426359B2 (en) 2022-08-30
US12070521B2 (en) 2024-08-27
BR112016027143A8 (pt) 2021-06-29
JP2020055822A (ja) 2020-04-09
JP2017524685A (ja) 2017-08-31
WO2015177209A1 (en) 2015-11-26
CN106456567A (zh) 2017-02-22
JP6895755B2 (ja) 2021-06-30
US20220296531A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US12070521B2 (en) Method for adjusting the release of active agent in a transdermal delivery system
US20230248661A1 (en) Transdermal Delivery System Containing Rotigotine
US12427119B2 (en) Transdermal delivery system including an interface mediator
JP2020532582A (ja) リバスチグミンの経皮投与のための経皮治療システム
CA3162229A1 (en) Transdermal therapeutic system containing agomelatine
EP3764999A1 (en) Transdermal therapeutic system containing nicotine and silicone acrylic hybrid polymer
JP2020525546A (ja) スコポラミン及びシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
WO2024160939A1 (en) Transdermal therapeutic system for the transdermal administration of huperzine a
HK40100478A (en) Transdermal delivery system including an interface mediator
US20220241216A1 (en) Transdermal therapeutic system comprising an active agent-containing layer comprising an acrylic polymer and a skin contact layer comprising a silicone gel adhesive
WO2023062201A1 (en) Transdermal therapeutic system for the transdermal administration of tizanidine
BR112016027143B1 (pt) Uso de um aditivo em um sistema terapêutico transdérmico, e método para ajuste do período de permeação de um sistema terapêutico transdérmico
HK1236094A1 (en) Transdermal delivery system containing rotigotine
HK1236094B (en) Transdermal delivery system containing rotigotine
HK1236096B (en) Transdermal delivery system including an interface mediator
HK1236096A1 (en) Transdermal delivery system including an interface mediator

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200520

EEER Examination request

Effective date: 20200520

EEER Examination request

Effective date: 20200520

EEER Examination request

Effective date: 20200520

EEER Examination request

Effective date: 20200520

EEER Examination request

Effective date: 20200520